Company intelligence / Profile preview
Merz Therapeutics
Frankfurt am Main, Hesse, Germanymerztherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Merz Therapeutics has commercial products for neurological and movement disorders, including botulinum neurotoxin A for dystonia, spasticity, chronic sialorrhea, as well as therapies for Alzheimer’s disease and chronic liver disease. In 2024, acquisitions expanded the pipeline to include inhaled levodopa for Parkinson’s and sustained-release formulations for multiple sclerosis. Ongoing clinical development targets expansion of existing and new indications for neurotoxins and neurology products.[5][3][6]
- Therapeutic areas
- NeurologyDermatologyGastroenterology
- Modalities
- Small moleculeBiologicBotulinum neurotoxinProtein
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Teijin Pharma (Japan, botulinum neurotoxin marketing partner)SAFE (Stroke Alliance for Europe, patient awareness/engagement)Dystonia Europe (patient advocacy)
Beyond the preview
Go deeper on Merz Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Merz Therapeutics.